Format

Send to

Choose Destination
Bull Cancer. 2018 Dec;105 Suppl 1:S59-S67. doi: 10.1016/S0007-4551(18)30391-6.

Immunothérapie des glioblastomes.

[Article in French]

Author information

1
Gustave-Roussy, université Paris-Saclay, Drug Development Department (DITEP), Villejuif, F-94805, France. Electronic address: capucine.baldini@gustaveroussy.fr.
2
Gustave-Roussy, université Paris-Saclay, Drug Development Department (DITEP), Villejuif, F-94805, France.
3
Gustave-Roussy, université Paris-Saclay, Department of Medical Oncology, Villejuif, F-94805, France.
4
Gustave-Roussy, université Paris-Saclay, Radiation Oncology Department, Villejuif, F-94805, France.

Abstract

Targeting the immune system as a therapeutic strategy in solid tumors has shown great efficacy in various tumor types. However the role and success of this approach in glioblastomas remain to be determined. Recent studies demonstrated that central nervous system is no longer considered as an immunoprivileged sanctuary with impressive immune response without blood brain barrier's disruption. Improving our understanding of immune privilege in the central nervous system could lead to better treatment strategies in gliobastomas. This review focuses on describing the immune system in the central nervous system and immuno-therapeutic strategies under development in glioblastomas.

KEYWORDS:

CNS; Glioblastoma; Glioblastome; Immune checkpoint; Immunotherapy; Immunothérapie; Inhibiteurs du point; SNC; de contrôle; immunitaire; inhibitors

PMID:
30595200
DOI:
10.1016/S0007-4551(18)30391-6
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center